Valuation : iTeos Therapeutics, Inc.

Market Cap 45Cr 39Cr 36Cr 33Cr 62Cr 4.29TCr 63Cr 430.08Cr 167.8Cr 2.16TCr 168.46Cr 164.79Cr 7.18TCr P/E 2023
-3.48x
P/E 2024 -2.31x
Enterprise Value -4.09Cr -3.52Cr -3.3Cr -3.01Cr -5.68Cr -390.58Cr -5.7Cr -39Cr -15Cr -197.16Cr -15Cr -15Cr -653.77Cr EV / Sales 2023
-1,06,40,152x
EV / Sales 2024 -59,70,615x
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
3 years 4.8
Extreme 4.8
18.75
5 years 4.8
Extreme 4.8
52.43
10 years 4.8
Extreme 4.8
52.43
Manager TitleAgeSince
Chief Executive Officer 59 28/08/2025
Chief Operating Officer - 28/08/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 59 28/08/2025
Date Insider Type Main position Quantity % Market Cap.
29/08/25 Tender

Chief Technology Officer

2,22,423 0.5811%
29/08/25 Tender

Chief Executive Officer; Director

11,06,638 2.8914%
29/08/25 Tender

Chief Operating Officer

5,78,671 1.5119%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-.--%-.--%-17.14% 45Cr
-1.59%-3.35%+52.37%+93.70% 6.95TCr
-1.34%-0.75%+48.21%+91.86% 6.5TCr
+0.30%-0.69%+52.56%+10.23% 2.65TCr
-2.35%-5.75%-12.90%+448.54% 2.59TCr
-8.37%-12.43%+2.08%-16.71% 2.56TCr
-0.96%+10.36%+283.06%+436.50% 2.02TCr
-0.51%+0.23%+35.77%-18.70% 2TCr
-1.91%-4.37%+13.28%+535.19% 1.57TCr
-1.47%+0.68%+45.51%+143.08% 1.35TCr
Average -1.80%-1.73%+51.99%+170.65% 2.82TCr
Weighted average by Cap. -1.93%-1.50%+53.64%+151.24%

Financials

2023 2024
Net sales 12.6 10.85 10.18 9.29 17.5 1.2T 17.55 120.73 47.1 607.65 47.29 46.26 2.01T 35 30.16 28.28 25.81 48.63 3.35T 48.78 335.49 130.9 1.69T 131.41 128.55 5.6T
Net income -11Cr -9.71Cr -9.1Cr -8.31Cr -16Cr -1.08TCr -16Cr -107.97Cr -42Cr -543.44Cr -42Cr -41Cr -1.8TCr -13Cr -12Cr -11Cr -9.91Cr -19Cr -1.28TCr -19Cr -128.84Cr -50Cr -648.48Cr -50Cr -49Cr -2.15TCr
Net Debt -53Cr -45Cr -42Cr -39Cr -73Cr -5.03TCr -73Cr -504.06Cr -196.67Cr -2.54TCr -197.43Cr -193.14Cr -8.41TCr -49Cr -42Cr -40Cr -36Cr -68Cr -4.68TCr -68Cr -469.26Cr -183.09Cr -2.36TCr -183.8Cr -179.8Cr -7.83TCr
Logo iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Employees
173
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITOS Stock